Empagliflozin/metformin
Empagliflozin/Metformin
Empagliflozin/Metformin (pronunciation: em-pa-gli-flo-zin/met-for-min) is a combination medication used in the treatment of Type 2 diabetes.
Etymology
The term Empagliflozin is derived from the chemical name of the drug, which is a sodium-glucose co-transporter-2 (SGLT2) inhibitor. Metformin is derived from the French word 'metformine', which is based on the chemical name of the drug, a biguanide antihyperglycemic agent.
Usage
Empagliflozin/Metformin is used to improve glycemic control in adults with Type 2 diabetes when treatment with both empagliflozin and metformin is appropriate. It is often used when diet and exercise alone does not control high blood sugar.
Mechanism of Action
Empagliflozin works by blocking the reabsorption of glucose by the kidney, increasing glucose excretion, and lowering blood glucose levels. Metformin works by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization.
Related Terms
- Type 2 diabetes
- Sodium-glucose co-transporter-2 (SGLT2) inhibitors
- Biguanide antihyperglycemic agents
- Glycemic control
- Insulin sensitivity
External links
- Medical encyclopedia article on Empagliflozin/metformin
- Wikipedia's article - Empagliflozin/metformin
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski